<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123929</url>
  </required_header>
  <id_info>
    <org_study_id>05/117</org_study_id>
    <nct_id>NCT00123929</nct_id>
  </id_info>
  <brief_title>Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer</brief_title>
  <official_title>Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer
      are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100
      mg/m2 e3w). After the fourth cycle, patients are submitted to surgery to ascertain
      pathological response. They then receive the opposite drug, hormones, Herceptin, and
      radiation as indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to define the genetic signature which predicts the response to single
      drug doxorubicin versus docetaxel. 250 patients will be included. cDNA microarrays will be
      produced and the genetic pattern will be correlated with the response to doxorubicin and
      docetaxel. Secondary aim is the prediction of response by means of IHC determinations (her2,
      ER, PgR, Ki67, protein TAU), FISH (topoisomerase II alpha, her2) and PCR (topoisomerase II
      alpha).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>correlation of genetic tumoral pattern with response to docetaxel versus doxorubicin</measure>
    <time_frame>2005-2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate to doxorubicin versus docetaxel</measure>
    <time_frame>2005-2013</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>100 mg/m2 every 3 weeks times 4</description>
    <arm_group_label>2</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>75 mg/m2 every 3 weeks times 4</description>
    <arm_group_label>1</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced, inoperable breast carcinoma or stage II not amenable to breast
             preserving surgery (amendment introduced on november 2006)

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &gt;75

          -  Cardiac disease; LEFT &lt;50%

          -  Hyperbilirubinemia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Diaz-Rubio, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Miguel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos, Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servicio de Oncologia Medica, Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2005</study_first_submitted>
  <study_first_submitted_qc>July 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Miguel Martin, MD</name_title>
    <organization>Hospital San Carlos</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>genetic signature</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

